Chute John P, Saini Abha A, Chute Dennis J, Wells Mark R, Clark William B, Harlan David M, Park Jenny, Stull Margaret K, Civin Curt, Davis Thomas A
Stem Cell Biology Laboratory, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), Navy Transplantation and Autoimmunity Branch, Bethesda, MD, USA.
Blood. 2002 Dec 15;100(13):4433-9. doi: 10.1182/blood-2002-04-1238. Epub 2002 Aug 1.
Adult human bone marrow (ABM) is an important source of hematopoietic stem cells for transplantation in the treatment of malignant and nonmalignant diseases. However, in contrast to the recent progress that has been achieved with umbilical cord blood, methods to expand ABM stem cells for therapeutic applications have been disappointing. In this study, we describe a novel culture method that uses human brain endothelial cells (HUBECs) and that supports the quantitative expansion of the most primitive measurable cell within the adult bone marrow compartment, the nonobese diabetic/severe combined immunodeficient (NOD/SCID) repopulating cell (SRC). Coculture of human ABM CD34(+) cells with brain endothelial cells for 7 days supported a 5.4-fold increase in CD34(+) cells, induced more than 95% of the CD34(+)CD38(-) subset to enter cell division, and produced progeny that engrafted NOD/SCID mice at significantly higher rates than fresh ABM CD34(+) cells. Using a limiting dilution analysis, we found the frequency of SRCs within fresh ABM CD34(+) cells to be 1 in 9.9 x 10(5) cells. Following HUBEC culture, the estimated frequency of SRCs increased to 1 in 2.4 x 10(5) cells. All mice that received transplants of HUBEC-cultured cells showed B-lymphoid and myeloid differentiation, indicating that a primitive hematopoietic cell was preserved during culture. Noncontact HUBEC cultures also maintained SRCs at a level comparable to contact HUBEC cultures, suggesting that cell-to-cell contact was not required. These data demonstrate that human brain endothelial cells possess a unique hematopoietic activity that increases the repopulating capacity of adult human bone marrow.
成人骨髓(ABM)是用于治疗恶性和非恶性疾病的造血干细胞移植的重要来源。然而,与脐带血最近取得的进展相比,用于治疗应用的ABM干细胞扩增方法一直令人失望。在本研究中,我们描述了一种新的培养方法,该方法使用人脑内皮细胞(HUBECs),并支持成人骨髓隔室内最原始可测量细胞即非肥胖糖尿病/严重联合免疫缺陷(NOD/SCID)重建造血细胞(SRC)的定量扩增。人ABM CD34(+)细胞与脑内皮细胞共培养7天,支持CD34(+)细胞增加5.4倍,诱导超过95%的CD34(+)CD38(-)亚群进入细胞分裂,并产生比新鲜ABM CD34(+)细胞以显著更高的比率植入NOD/SCID小鼠的后代。使用极限稀释分析,我们发现新鲜ABM CD34(+)细胞中SRC的频率为每9.9×10(5)个细胞中有1个。经过HUBEC培养后,SRC的估计频率增加到每2.4×10(5)个细胞中有1个。所有接受HUBEC培养细胞移植的小鼠都表现出B淋巴细胞和髓系分化,表明在培养过程中保留了一种原始造血细胞。非接触HUBEC培养也将SRC维持在与接触HUBEC培养相当的水平,表明不需要细胞间接触。这些数据表明,人脑内皮细胞具有独特的造血活性,可增加成人骨髓的重建造血能力。